Movers and SHAKERS
Onconova Therapeutics Inc. (ONTX)
Q1 2020 Earnings: 2020 Could Be Transformational for Onconova
Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company operating in the US. It focuses on discovering and developing novel small molecule product candidates primarily to treat cancer. The company has created a library of targeted agents designed to work against cellular pathways important to cancer cells. Its product candidates are Single-agent IV rigosertib, Oral rigosertib + azacitidine, IV Briciclib, Recilisib, and ON 123300. The key product candidate Rigosertib is a small molecule which blocks cellular signaling by targeting RAS effector pathways.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
INSPIRE topline data is set to readout in H2 2020. In Q1 2020, Onconova completed patient enrollment in pivotal Phase 3 INSPIRE trial evaluating rigosertib in 2nd-line high-risk myelodysplastic syndrome (HR-MDS) patients. The company plans to present topline data at a major conference (more likely ASH) in H2 2020.
Pipeline diversification in 2020. Besides the INSPIRE study, the company is on track to diversify its pipeline with additional programs including an investigator-initiated study of rigosertib plus nivolumab in Stage IV KRAS mutated lung adenocarcinoma and a randomized Phase 2/3 study of the combination of oral rigosertib plus azacytidine in 1st line HR-MDS patients (anticipated in 2020). Also, IND submission of ON123300 (CDK 4/6 + ARK5 inhibitor) program is anticipated Q4 2020. We believe these programs will generate value and...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.